Chronic administration of apple polyphenols ameliorates hyperglycaemia in high-normal and borderline subjects: A randomised, placebo-controlled trial
•12weeks apple polyphenol administration were assessed on high-normal and borderline types in a double-blinded, placebo-controlled clinical trial.•Apple polyphenol ameliorated postprandial hyperglycaemia in high-normal and borderline types. We previously reported that apple polyphenols (AP) and thei...
Saved in:
Published in | Diabetes research and clinical practice Vol. 129; pp. 43 - 51 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Ireland
Elsevier B.V
01.07.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | •12weeks apple polyphenol administration were assessed on high-normal and borderline types in a double-blinded, placebo-controlled clinical trial.•Apple polyphenol ameliorated postprandial hyperglycaemia in high-normal and borderline types.
We previously reported that apple polyphenols (AP) and their major active components, procyanidins, had beneficial effects on glucose homeostasis and diabetes in diabetic ob/ob mice. The present study was performed to evaluate the effects of chronic AP administration on glucose tolerance in high-normal and borderline human subjects.
Subjects (n=65) with a fasting plasma glucose (FPG) level of 100–125mg/dL determined during a recent health check-up were randomised to receive tablets containing AP (600mg/day) or placebo tablets for 12weeks in a double-blinded, placebo-controlled clinical trial. The primary outcome was insulin resistance, assessed using a 75g oral glucose tolerance test (OGTT).
The 12-week chronic administration of AP significantly reduced the increase in glucose at 30-min post-75g OGTT (OGTT30-min glucose) value, compared to the placebo regimen. Furthermore, in a subgroup of the high-normal (FPG value, 100–109mg/dL; 2-h post-75g OGTT glucose (OGTT2-h glucose) value, <140mg/dL) and borderline (FPG value, 110–125mg/dL; OGTT2-h glucose value, <140mg/dL and FPG value, <126mg/dL; OGTT2-h glucose value, 140–199mg/dL) subjects, OGTT30-min glucose value in the AP group (164.0±7.4mg/dL) was significantly lower than that of the placebo group (194.7±10.4mg/dL, p<0.05). No significant changes in the other lipid parameters and cytokine levels were observed.
Chronic AP administration significantly improved impaired glucose tolerance in high-normal and borderline subjects. Larger and/or longer-term scale human studies are required to confirm the potential glucose homeostasis of AP. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ISSN: | 0168-8227 1872-8227 1872-8227 |
DOI: | 10.1016/j.diabres.2017.03.028 |